EGFR and glioblastoma: In a GBM tumor, wild-type EGFR and EGFRvIII are co-expressed [65]; 97% of GBM cells express wild-type EGFR while 23% of GBM show a EGFRvIII mutation, which makes these two forms of EGFR the clinically most relevant [66].